Abvc biopharma announces vitargus® phase ii study plan approved by hrec in australia

Fremont, ca, oct. 05, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that its vitrargus phase ii study plan was approved by the australian bellberry human research ethics committee (hrec) on september 29, 2022.  subsequently, a clinical trial notification (ctn) was submitted to the australian therapeutic goods administration (tga) for the initiation of the study in australia.
ABVC Ratings Summary
ABVC Quant Ranking